XML 54 R38.htm IDEA: XBRL DOCUMENT v3.20.4
OPERATING BUSINESS SEGMENT AND INTERNATIONAL OPERATION INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Schedule of reportable business segment information
Reportable business segment information for the years ended December 31, 2020 and 2019 is as follows (dollar amounts in thousands):
Year Ended December 31,20202019
Net sales:  
Asia$138,717 $138,536 
Europe77,688 62,523 
North America145,481 138,163 
Latin America and Other23,319 22,993 
Total net sales385,205 362,215 
Contribution margin (1):  
Asia66,801 65,871 
Europe26,014 19,954 
North America50,193 49,327 
Latin America and Other9,771 9,713 
Total contribution margin152,779 144,865 
Selling, general and administrative (2)131,297 128,740 
Operating income21,482 16,125 
Other income (loss), net1,339 (483)
Income before provision for income taxes$22,821 $15,642 
___________________________
(1) Contribution margin consists of net sales less cost of sales and volume incentives expense.

(2)  Service fees in China totaled $11.7 million and $9.4 million for the years ended December 31, 2020 and 2019, respectively. These service fees are included in our selling, general and administrative expenses.
Year Ended December 31,20202019
Capital expenditures:  
Asia$542 $3,262 
Europe34 27 
North America4,267 2,605 
Latin America and Other62 21 
Total capital expenditures$4,905 $5,915 
Depreciation and amortization:  
Asia$1,919 $1,544 
Europe77 75 
North America8,673 8,855 
Latin America and Other74 125 
Total depreciation and amortization$10,743 $10,599 

As of December 31,20202019
Assets:  
Asia$82,572 $65,959 
Europe16,398 15,187 
North America142,324 124,337 
Latin America and Other8,204 7,585 
Total assets$249,498 $213,068 
Schedule of consolidated net sales revenue by geographical locations
From an individual country perspective, only the United States and South Korea comprise approximately 10 percent or more of consolidated net sales for the years ended December 31, 2020 and 2019 as follows (dollar amounts in thousands):
Year Ended December 31,20202019
Net sales:  
United States$134,976 $128,019 
South Korea62,041 70,556 
Other188,188 163,640 
Total net sales$385,205 $362,215 
Schedule of revenue generated by each of the Company's product lines
Revenue generated by each of our product lines is set forth below (dollars in thousands):
Year Ended December 31,20202019
Asia:  
General health$36,445 $37,795 
Immunity847 940 
Cardiovascular40,496 44,541 
Digestive32,605 24,434 
Personal care10,606 13,753 
Weight management17,718 17,073 
 138,717 138,536 
Europe:  
General health$32,822 $22,469 
Immunity8,231 5,130 
Cardiovascular10,863 10,672 
Digestive18,673 14,456 
Personal care4,663 7,463 
Weight management2,436 2,333 
 77,688 62,523 
North America:  
General health$61,897 $59,847 
Immunity23,036 15,341 
Cardiovascular15,852 18,750 
Digestive32,851 33,077 
Personal care7,587 6,170 
Weight management4,258 4,978 
 145,481 138,163 
Latin America and Other:  
General health$6,867 $6,919 
Immunity3,122 2,453 
Cardiovascular1,512 1,446 
Digestive9,863 10,258 
Personal care1,203 1,056 
Weight management752 861 
 23,319 22,993 
Total net sales$385,205 $362,215 
Schedule of consolidated property, plant and equipment by geographical locations
From an individual country perspective, only the United States comprise 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands):
As of December 31 20202019
Property, plant and equipment  
United States$50,025 $54,470 
Other4,330 5,042 
Total property, plant and equipment$54,355 $59,512